| Autor: |
Desai, S. H., Spinner, M., Evens, A. M., Bachanova, V., Goyal, G., Kahl, B., Dorritie, K., Azzi, J., Kenkre, V. P., Arai, S., Chang, C., Fusco, B., Sumransub, N., Hatic, H., Saba, R., Ibrahim, U., Harris, E. I., Ansell, S. M., Shah, H., Wagner‐Johnston, N. |
| Předmět: |
|
| Zdroj: |
Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p366-368, 3p |
| Abstrakt: |
B Conclusions: b In the era of novel agents, pts with relapsed cHL after ASCT were found to have a median OS reaching almost a decade. Prior to brentuximab vedotin (BV) and checkpoint inhibitors (CPI), the median overall survival (OS) of pts with cHL relapse after ASCT was 2-3 years. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text